Corvus Pharmaceuticals
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell CRVS and other ETFs, options, and stocks.About CRVS
Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor.
CRVS Key Statistics
Stock Snapshot
With a market cap of 567.58M, Corvus Pharmaceuticals(CRVS) trades at $7.40. The stock has a price-to-earnings ratio of -14.21.
On 2025-11-10, Corvus Pharmaceuticals(CRVS) stock traded between a low of $7.01 and a high of $7.78. Shares are currently priced at $7.40, which is +5.6% above the low and -4.9% below the high.
Corvus Pharmaceuticals(CRVS) shares are trading with a volume of 946.49K, against a daily average of 1.25M.
During the past year, Corvus Pharmaceuticals(CRVS) stock moved between $2.54 at its lowest and $10.00 at its peak.
During the past year, Corvus Pharmaceuticals(CRVS) stock moved between $2.54 at its lowest and $10.00 at its peak.
CRVS News
Corvus Pharmaceuticals Inc. ((CRVS)) has held its Q3 earnings call. Read on for the main highlights of the call. Elevate Your Investing Strategy: Take advantage...
Corvus Pharmaceuticals Inc. ( (CRVS) ) has released its Q3 earnings. Here is a breakdown of the information Corvus Pharmaceuticals Inc. presented to its investo...
Earnings Call Insights Corvus outlines January data readout for soquelitinib extension study as Phase II atopic dermatitis trial set for Q1 2026 Nov. 04, 2025 7...
